Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).

Participants needed: 240
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Updated: Sep 22, 2026Locations: 24
Eligibility criteria

Adult male and female aged ≥18 years; [+7]

Known causes of secondary hypertension: renal artery stenosis, uncontrolled or u... [+15]

Read more
Status: Recruiting

VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.

Participants needed: 86
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Updated: Nov 28, 2025Locations: 2
Eligibility criteria

Voluntarily participate in clinical trials, understand the nature of the study a... [+4]

Known allergy to aldosterone synthase inhibitors or any components/excipients of... [+20]

Read more
Status: Recruiting

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Participants needed: 188
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Updated: Feb 11, 2025Locations: 1
Eligibility criteria

Age ≥ 18 at the time of screening; [+4]

Major surgery within 4 weeks of the first dose of study treatment. [+2]

Read more